The TGA has published a new set of test results for oil and flower products amid ongoing uncertainty around the regulation of imported medicinal cannabis. Cannabiz editor-at-large Rhys Cohen analyses what it means for the industry.

The Therapeutic Goods Administration (TGA) has published new testing results for several medicinal cannabis products, all of which have been found to comply with the relevant quality standards.

This is good news for the companies that had their products tested. Unlike last year, when a similar testing exercise was undertaken, no-one is contesting the methodology or accuracy of these tests.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

In 2020, the TGA selected the top 25 medicinal cannabis products (by volume of SAS approvals) to be tested for compliance with TGO93 potency and labelling requirements. This included oil, flower and capsule products in both Schedule 4 and Schedule 8.

This time around the TGA’s analysis has been more focused. Instead of sampling the top 25 products in the market, it has narrowed in on Schedule 4 oral oil products “used in the paediatric population”, and on flower products.

The Schedule 4 oral oils were tested for potency and labelling compliance. All products tested were within +/- 10% of their labelled potency. The flower products were tested for toxin levels. Aflatoxins, heavy metals, ochratoxin A, and pesticides were all below the required levels.

Cannabiz editor-at-large Rhys Cohen

According to a TGA spokesperson, this was a “routine compliance monitoring exercise” and there were no specific concerns that led to the examination of the potency of CBD oils approved for paediatric patients, or the toxin levels in flower products.

The TGA told Cannabiz how the CBD oil products were selected.

“As at July 31 2021, 157 different unapproved medicinal cannabis products have been accessed via the SAS Category B pathway for patients under 17 years of age. The TGO93 paediatric laboratory survey aimed to analyse cannabidiol (CBD) products that are mainly prescribed in the paediatric population. The samples were targeted based on the top 50 supplied CBD products by volume.”